|[September 05, 2014]
Research and Markets: Future Horizons and Growth Strategies in the European Infectious Disease Testing Market 2014: Supplier Shares and Country Forecasts
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/3wzhwh/future_horizons)
has announced the addition of the "Future
Horizons and Growth Strategies in the European Infectious Disease
Testing Market 2014: Supplier Shares and Country Forecasts"
report to their offering.
This is a new strategic analysis of major business opportunities
emerging in the infectious disease testing market during the next five
years. The report examines key trends in five major European countries
(France, Germany, Italy, Japan and UK) reviews current and emerging
assays; analyzes potential applications of innovative diagnostic
technologies; forecasts volume and sales for over 100 infectious disease
tests by assay, market segment, and country; provides test volume
estimates by method (molecular, serology/immunodiagnostics,
culture/microscopy); profiles leading players and potential market
entrants; and suggests alterntive business expansion strategies for
This comprehensive seven-country report will assist diagnostics industry
executives, as well as companies planning to diversify into the dynamic
and rapidly expanding microbiology testing market, in evaluating
emerging opportunities and developing effective business strategies.
Microbiology testing is one of the most rapidly growing segments of the
in vitro diagnostics industry, and the greatest challenge facing
suppliers during this decade. Among the main driving forces is
continuing spread of AIDS, which remains the world's major health threat
and a key factor contributing to the rise of opportunistic infections;
threat of bioterrorism; advances in molecular diagnostic technologies;
and a wider availability of immunosuppressive drugs.
Although for some infections the etiology is still a mystery, while for
others the causative microorganisms are present in minute concentrations
long before the occurrence of first clinical symptoms, recent advances
in genetic engineering and detection technologies are creating exciting
opportunities for highly sensitive, specific and cost-effective products.
Infectious Diseases Analyzed in the Report
AIDS/HIV, Adenovirus, Aeromonads, Bartonella, Blastocystis Hominis,
Campylobacter, Candida, Chancroid, Chlamydia, Clostridium, Coronavirus,
Coxsackievirus, Cryptosporidium, Cyclospora, CMV, E. Coli, Echovirus,
Encephalitis, Enterovirus, EBV, Giardia, Gonorrhea, Granuloma Inguinale,
Hantavirus, H. Pylori, Hepatitis, Herpes Influenza, Legionella, Lyme
disease, Lymphogranuloma, Malaria, Measles, Meningitis, Microsporidium,
Mononucleosis, Mumps, Mycoplasma, HPV, Parvovirus, Pneumonia,
Polyomaviruses, Pseudomonas, Rabies, RSV, Rhinovirus, Rotavirus ,
Rubella, Salmonella, Septicemia, Shigella, Staphylococci, Streptococci,
Syphilis, Toxoplasmosis, Trichomonas, TB, Vibrio, West Nile, Yersinia.
For more information visit http://www.researchandmarkets.com/research/3wzhwh/future_horizons
[ Back To TMCnet.com's Homepage ]